论文部分内容阅读
近年来,我国前列腺癌（Prostatic Cancer,CaP）和前列腺增生（Benigprosatic hyperplasia,BPH）的发病率增长迅速,其中CaP占男性发病率的第二位,死亡率的第三位。众所周知,前列腺特异性抗原（PSA）是目前临床上检测CaP最理想的指标,其敏感性较高,已被广泛应用CaP的早期诊断、疗效监测和随访等方面,但其特异性较低,为此,我们应用放射免疫分析法对81例CaP和103例BPH等患者及45例正常人的血清PSA、前列腺酸性磷酸酶（PAP）和癌胚抗原（CEA）进行联合检测旨在于提高特异性,现报道如下。 材料和方法 一、材料: （一）正常对照组:45例,年龄24～73岁,平均46.4岁,系本院健康体检者,各项检查均无异常发现。 （二）患病组:202例,其中CaP 81例,BPH 103例,膀胱癌11例,阴茎癌7例。年龄43～82岁,平均55.6岁。所有患者均经临床及影像学诊断证实,部分
In recent years, the incidence of Prostatic Cancer (CaP) and Benign Prostate Hyperplasia (BPH) has been rapidly increasing in China. CaP is the second most common cause of morbidity and the third leading cause of death in China. As we all know, prostate specific antigen (PSA) is the most ideal clinical detection of CaP indicators, its high sensitivity, has been widely used in the early diagnosis of CaP, efficacy monitoring and follow-up, etc., but its specificity is low, as We used radioimmunoassay to detect serum PSA, prostatic acid phosphatase (PAP) and carcinoembryonic antigen (CEA) in 81 cases of CaP, 103 cases of BPH and 45 cases of normal people. The aim is to improve the specificity, Report as follows now. Materials and methods First, the material: (a) normal control group: 45 cases, aged 24 to 73 years, mean 46.4 years of age, Department of Health, physical examination, the examination showed no abnormalities. (B) the prevalence group: 202 cases, of which 81 cases of CaP, BPH 103 cases, 11 cases of bladder cancer, 7 cases of penile cancer. Age 43 ~ 82 years old, with an average of 55.6 years old. All patients were confirmed by clinical and imaging diagnosis, in part